Scientific Program

Thursday, September 27, 2018

Hall A
14:00-15:30 Hematology hot news session
Chairs: Mohamad Mohty, France; Arnon Nagler, Israel
14:00-14:30 Introduction to IACH
Meeting Co-Chairs
14:30-14:40 Ibrutinib plus Venetoclax for the treatment of mantle-cell lymphoma
Olivier Hermine, France
14:40-14:50 Ivosidenib in mutant IDH1 relapsed/refractory acute myeloid leukemia
Norbert Vey, France
14:50-15:00 Letermovir prophylaxis for CMV in hematopoietic-cell transplantation
Bipin Savani, USA
15:00-15:10 Management of hairy cell leukemia – an update
Elena Solomou, Greece
15:10-15:20 The RELEVANCE study: Lenalidomide and Rituximab vs Chemotherapy and Rituximab in untreated follicular lymphoma
Gandhi Damaj, France
15:20-15:30 Update on therapy of sickle cell disease
Selim Corbacioglu, Germany
15:30-16:00 Coffee Break
16:00-17:15 Plenary session 1: New frontiers and novel drugs in hematology: from the bench to the bedside
Chairs: Norbert-Claude Gorin, France; Bipin Savani, USA
16:00-16:20 Novel anticoagulation agents
Gili Kenet, Israel
16:20-16:40 CAR-T cells in multiple myeloma
Hermann Einsele, Germany
16:40-17:00 Advances in CLL therapy
Mohamad Kharfan-Dabaja, USA
17:00-17:20 Modulation of the microbiome
Philippe Langella, France
17:20-17:30 Discussion
17:30-17:45 Break
17:45-19:00 Opening session: Keynote opening lectures and awards
Chairs: Mohamad Mohty, France; Arnon Nagler, Israel
17:45-18:00 Award presentation (H.J. Khoury Excellence in Research Award)
18:00-18:30 Multiple myeloma – past, present and future
Jean-Luc Harousseau, France
18:30-19:00 Advances in the treatment of acute lymphoblastic leukemia
Hagop Kantarjian, USA
19:00 Welcome Reception

Friday, September 28, 2018

Hall A Hall B
09:00-10:30 Session F1A: Multiple myeloma
Chairs: Meral Baksaç, Turkey; Mohamad Mohty, France
09:00-10:30 Session F1B: Allogeneic stem cell transplant indications
Chairs: Ibrahim Yakoub-Agha, France; Marcos de Lima, USA
09:00-09:20 Debate: Chemo-free stem cell mobilization in myeloma
Con: Rafael Duarte, Spain
09:00-09:20 Acute lymphoblastic leukemia
Sebastian Giebel, Poland
09:20-09:40 Pro: Christian Chabannon, France 09:20-09:40 Acute myeloid leukemia
Arnon Nagler, Israel
09:40-10:00 The patient perspective – examples from multiple myeloma
Karthik Ramasamy, UK
09:40-10:00 Myelodysplastic syndromes
Ibrahim Yakoub-Agha, France
10:00-10:20 Monoclonal antibodies in myeloma
Mohamad Mohty, France
10:00-10:20 Myeloproliferative neoplasms
Marcos de Lima, USA
10:20-10:30 Discussion 10:20-10:30 Discussion
10:30-11:00 Coffee Break, Poster Viewing and Visit Exhibition
11:00-12:30 Session F2A: Acute myeloid leukemia (AML)
Chairs: Jose Eduardo Guimaraes, Portugal; Bob Löwenberg, Netherlands
11:00-12:30 Session F2B: Cellular and immune therapy in hematologic malignancies
Chairs: Christian Chabannon, France; Jürgen Kuball, Netherlands
11:00-11:20 Role of MRD in AML
Maria Gilleece, UK
11:00-11:20 The case for gamma-delta T cells
Jürgen Kuball, Netherlands
11:20-11:40 Management of elderly AML
Farhad Ravandi, USA
11:20-11:40 Calcineurin and mTOR inhibitor-free GvHD prophylaxis:
Samer Al-Homsi, USA
11:40-12:00 How to improve on “3+7”?
Bob Löwenberg, Netherlands
11:40-12:00 Intersection between immunology and metabolic complications after HCT
Brian Engelhardt, USA
12:00-12:20 Supportive care in AML
Bipin Savani, USA
12:00-12:20 What role could allotransplantation have in CAR-T cell therapy?
Stephan Mielke, Sweden
12:20-12:30 Discussion 12:20-12:30 Discussion
12:30-12:45 Lunch Box Pick-up
12:45-13:45 Industry Symposium
Hall A
13:45-14:00 Short Break
14:oo-15:30 Session F3A: Non-Hodgkin lymphoma
Chairs: Christian Gisselbrecht, France; Mohamad Kharfan-Dabaja, USA
14:00-15:30 Session F3B: Allogeneic stem cell transplant complications
Chairs: Multu Arat, Turkey; Enric Carreras, Spain
14:00-14:20 Advances in lymphoma biology
Fabrice Jardin, France
14:00-14:20 Management of endothelium-related complications
Enric Carreras, Spain
14:20-14:40 Therapy of high grade lymphoma
Christian Gisselbrecht, France
14:20-14:40 Management of viral infections
Per Ljungman, Sweden
14:40-15:00 Therapy of HTLV-related lymphoma
Ali Bazarbachi, Lebanon
14:40-15:00 Management of acute GVHD
Florent Malard, France
15:00-15:20 Advances in Waldenström Macroglobulinemia:
Irene Ghobrial, USA
15:00-15:20 Prevention and management of long term complications
Grzegorz Basak, Poland
15:20-15:30 Discussion 15:20-15:30 Discussion
15:30-16:00 Coffee Break, Poster Viewing and Visit Exhibition
16:00-17:30 Session F4A: Acute lymphoblastic leukemia (ALL)
Chairs: Sebastian Giebel, Poland; Elias Jabbour, USA
16:00-17:30 Session F4B: Advances in allogeneic stem cell transplantation
Chairs: Didier Blaise, France; Steven Pavletic, USA
16:00-16:20 Risk stratification and MRD in ALL:
Christopher Hourigan, USA
16:00-16:20 Choice of donors for haplo-identical transplantation
Yu Wang, China
16:20-16:40 Novel antibodies in relapsed/refractory ALL
Eolia Brissot, France
16:20-16:40 Results of haplo transplants in acute leukemia
Didier Blaise, France
16:40-17:00 Intensive therapy for ALL
Dieter Hoelzer, Germany
16:40-17:00 Results of cord blood transplants in children
Annalisa Ruggeri, France/Italy
17:00-17:20 Management of elderly ALL
Elias Jabbour, USA
17:00-17:20 Novel therapies for chronic GVHD
Steven Pavletic, USA
17:20-17:30 Discussion 17:20-17:30 Discussion
17:30-18:30 Session F5A: Towards personalized and precision medicine
Chairs: Annalisa Ruggeri, Italy; Takanori Teshima, Japan
17:30-18:30 Session F5B: Case report forum
Chairs: Manuel Abecasis, Portugal; Mohamad Mohty, France
17:30-17:50 Treatment of non-transplant eligible myeloma
Thierry Facon, France
17:30-17:50 How to write a good paper?
Junia Melo, Australia
17:50-18:10 Pharmacogenomics in stem cell transplantation
Shahrukh Hashmi, USA
17:50-18:00 Case No. 1
Zina Peric, Croatia
18:10-18:30 Check-point inhibitors, immune-related adverse events, and GVHD
Takanori Teshima, Japan
18:00-18:10 Case No. 2
Jean El-Cheikh, Lebanon
18:10-18:20 Case N0. 3
Rémy Duléry, France
18:20-18:30 Discussion
18:30-19:00 Dinner Buffet
19:00-20:00 Industry Symposium
Hall A
20:00 Dessert and Coffee

Saturday, September 29, 2018

Hall A Hall B
08:30-10:00 Session S1A: Chronic myeloid leukemia (CML) and polycythemia vera
Chairs: Francois Guilhot, France; Giuseppe Saglio, Italy
08:30-10:00 Session S1B: Red blood cell disorders
Chairs: Borje Andersson, USA; Ali Taher, Lebanon
08:30-08:50 Update on polycythemia vera therapy
Nicole Casadevall, France
08:30-08:50 Advances in thalassemia
Ali Taher, Lebanon
08:50-09:10 Long term results of 1st generation TKI
Francois Guilhot, France
08:50-09:10 Advances in sickle cell disease
Miguel Abboud, Lebanon
09:10-09:30 Role of second generation TKI
Giuseppe Saglio, Italy
09:10-09:30 Transfusions in red blood cell disorders
France Pirenne, France
09:30-09:50 Stopping TKIs: for whom, when and how?
Francois-Xavier Mahon, France
09:30-09:50 Allogeneic stem cell transplantation for thalassemia and SCD
Borje Andersson, USA
09:50-10:00 Discussion 09:50-10:00 Discussion
10:00-11:00 Special Session: CAR-T cells – a real-life perspective
Chairs: Mohamad Mohty, France; Arnon Nagler, Israel
Hall A

10:00-10:20 Cell procurement for CAR-T cells manufacturing:
Christian Chabannon, France
10:20-10:40 CAR-T Cells: indications and focus on multiple myeloma:
Ali Bazarbachi, Lebanon
10:40-11:00 Management of CAR-T cell toxicities: a real-life example:
Mohamad Mohty, France
11:00-11:30 Coffee Break, Poster Viewing and Visit Exhibition
11:30-13:00 Session S2A: Myelodysplastic syndromes, aplastic anemia and other related disorders
Chairs: Urpu Salmenniemi, Finland; Carlos Vallejo, Spain
11:30-13:00 Session S2B: Rare diseases and orphan conditions
Chairs: Miguel Abboud, Lebanon; Olivier Hermine, France
11:30-11:50 Genetic predisposition in bone marrow failure and MDS
Jean Soulier, France
11:30-11:50 Systemic mastocytosis
Olivier Hermine, France
11:50-12:10 Management of low risk MDS
Pierre Fenaux, France
11:50-12:10 Replacement therapy in hemophilia – From proteins to genes
Alok Srivastava, India
12:10-12:30 2nd line ITP treatment
James Bussel, USA
12:10-12:30 Gaucher disease
Ari Zimran, Israel
12:30-12:50 Management of aplastic anemia outside transplant
Carlos Vallejo, Spain
12:30-12:50 Thrombotic thrombocytopenic purpura
Paul Coppo, France
12:50-13:00 Discussion 12:50-13:00 Discussion
13:00-13:15 Lunch Box Pick-up
13:15-14:15 Industry symposium 13:15-14:15 Session S3B: IACH lunch debate
Chairs: Michel Delforge, Belgium; Graham Jackson, UK
Autologous stem cell transplant for systemic amyloidosis
13:15-13:35 Pro: Giovanni Palladini, Italy
13:35-13:55 Con: Arnaud Jaccard, France
13:55-14:15 Discussion
14:15-14:25 Short Break
14:25-14:55 Session S4A: Clinical experiences from around the world
Chairs: Norbert-Claude Gorin, France; Shinichiro Okamoto, Japan
14:25-14:55 Session S4B: Making the right diagnosis and therapy
Chairs: Miguel-Angel Perales, USA; Anna Sureda, Spain
 14:25-14:40 China
He Huang, China
14:25-14:45 Transplant indications in Hodgkin lymphoma
Anna Sureda, Spain
14:40-14:55 Argentina
Gregorio Jaimovich, Argentina
14:45-15:05 Monoclonal component
Graham Jackson, UK
14:55-15:10 Turkey
Meral Beksac, Turkey
15:05-15:25 Hyperferritinemia
Pierre Brissot, France
15:10-15:25 Japan
Shinichiro Okamoto, Japan
15:25-15:45 MRD-driven therapy in myeloma
Michel Delforge, Belgium
15:25-15:40 India
Lalit Kumar, India
15:45-15:55 Discussion
15:40-15:55 Hong Kong
James Chim, Hong Kong
15:55-16:10 Presentation of the IACH ICA Award
Hall A
16:10-16:30 Coffee Break, Poster Viewing and Visit Exhibition
16:30-18:00 Plenary session 2: CAR-T cells in hematology
Hall A
Chairs: Mohamad Mohty, France; Arnon Nagler, Israel
16:30-16:50 CAR-T cells explained to clinicians
Elad Jacoby, Israel
16:50-17:10 Results of CAR-T cells in acute lymphoblastic leukemia
Jordan Gauthier, USA
17:10-17:30 Results in non-Hodgkin lymphoma and CLL
Miguel-Angel Perales, USA
17:30-17:50 NK CAR cells: current status and perspectives
Katy Rezvani, USA
17:50-18:00 Discussion
18:00 Meeting conclusions and closure